Skip to main content
Premium Trial:

Request an Annual Quote

Quotient, Theradiag Announce Dx Partnership

NEW YORK – Quotient Limited said on Wednesday that it will work with Theradiag to develop autoimmune diagnostics on Quotient's MosaiQ platform.

Eysins, Switzerland-based Quotient said that it intends to develop a microarray-based test for connective tissue diseases with Theradiag, which has agreed to provide Quotient with autoimmune reagents and multi-constituent quality controls.

Financial and other terms of the deal were not disclosed.

Quotient CEO Manuel Mendez in a statement called the collaboration with Theradiag a "key step" to offering a test for CTD based on a multimodal, multiplexed array, rather than conventional anti-nuclear antibody and extractable nuclear antigen antibody screening.

"This agreement will save Quotient product development time and related R&D expenses, allowing us to get to market faster and at a lower cost than if we developed the new products on our own," Mendez added.

The company noted in its statement that, according to its own estimates, the autoimmune diagnostics market could be a lucrative one, providing an addressable opportunity of $2 billion for its MosaiQ platform. Quotient already has several clinical microarray tests on the market. It announced a CE-IVD mark for its extended immunohematology microarray in March.